You are here: Industry Insights > Kerendia

News List

Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients pharmatimes
July 15, 2021
Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the US to slow chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D).
Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes expresspharma
July 12, 2021
Bayer announced the United States (US) Food and Drug Administration (FDA) has approved KERENDIA (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline ...
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes drugs
July 12, 2021
Bayer announced today the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death.
FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complications in Adults with Chronic Kidney Disease Associated with Type 2 Diabetes fda.gov
July 12, 2021
FDA has approved Kerendia (finerenone) tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated.